MCP
Mirador Capital Partners’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.23M | Buy |
158,717
+30,843
| +24% | +$628K | 0.52% | 41 |
|
|
2025
Q1 | $2.32M | Buy |
127,874
+8,382
| +7% | +$152K | 0.41% | 52 |
|
|
2024
Q4 | $3.02M | Buy |
119,492
+3,345
| +3% | +$84.5K | 0.55% | 42 |
|
|
2024
Q3 | $3.95M | Buy |
116,147
+3,768
| +3% | +$128K | 0.71% | 39 |
|
|
2024
Q2 | $4.16M | Buy |
112,379
+7,620
| +7% | +$282K | 0.78% | 34 |
|
|
2024
Q1 | $4.4M | Sell |
104,759
-3,151
| -3% | -$132K | 0.84% | 34 |
|
|
2023
Q4 | $4.28M | Buy |
107,910
+92
| +0.1% | +$3.65K | 0.91% | 28 |
|
|
2023
Q3 | $2.97M | Buy |
107,818
+3,103
| +3% | +$85.4K | 0.68% | 37 |
|
|
2023
Q2 | $3.55M | Buy |
104,715
+3,826
| +4% | +$130K | 0.84% | 34 |
|
|
2023
Q1 | $3.63M | Sell |
100,889
-4,669
| -4% | -$168K | 0.86% | 35 |
|
|
2022
Q4 | $4.7M | Sell |
105,558
-1,570
| -1% | -$70K | 1.11% | 24 |
|
|
2022
Q3 | $3.01M | Buy |
107,128
+760
| +0.7% | +$21.4K | 0.73% | 38 |
|
|
2022
Q2 | $2.87M | Buy |
106,368
+16,320
| +18% | +$440K | 0.68% | 43 |
|
|
2022
Q1 | $3.07M | Buy |
90,048
+3,996
| +5% | +$136K | 0.62% | 45 |
|
|
2021
Q4 | $3.33M | Buy |
86,052
+12,336
| +17% | +$477K | 0.7% | 44 |
|
|
2021
Q3 | $3.98M | Sell |
73,716
-4,963
| -6% | -$268K | 0.9% | 33 |
|
|
2021
Q2 | $2.63M | Buy |
78,679
+3,003
| +4% | +$100K | 0.6% | 51 |
|
|
2021
Q1 | $1.56M | Buy |
75,676
+48,927
| +183% | +$1.01M | 0.4% | 67 |
|
|
2020
Q4 | $469K | Buy |
26,749
+1,283
| +5% | +$22.5K | 0.13% | 118 |
|
|
2020
Q3 | $378K | Buy |
25,466
+6,332
| +33% | +$94K | 0.12% | 121 |
|
|
2020
Q2 | $249K | Buy |
19,134
+7,802
| +69% | +$102K | 0.09% | 134 |
|
|
2020
Q1 | $27K | Buy |
+11,332
| New | +$27K | 0.01% | 137 |
|